MTSR Metsera, Inc.
NASDAQHealthcareAs of 2025-11-13 16:00
Why MTSR matters now
Metsera, Inc. (MTSR) is a US stock in Healthcare. The latest InvestLog snapshot shows $70.50 with -0.35% on the session and $7.43B in market capitalization.
The latest indexable market news headline is "Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside" from Proactive Investors.
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
Beta
1.70
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.